OncoMatch/Clinical Trials/NCT04316364
A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
Is NCT04316364 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin and SHR-1316、Chemotherapeutic for non-small-cell lung cancer.
Treatment: SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin · SHR-1316、Chemotherapeutic — This trial is designed to evaluate the efficacy, safety and immunogenicity of neoadjuvant treatment with monoclonal antibody SHR-1316 or placebo in combination with platinum doublet chemotherapy in participants with resectable Stage II, IIIA, or selected IIIB non-small cell lung cancer (NSCLC) followed by adjuvant SHR-1316 or placebo and monitoring.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Disease stage
Required: Stage II, IIIA, SELECTED IIIB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systematic anti-cancer therapy
Any previous systematic anti-cancer therapy for lung cancer
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify